Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
New Life Sciences Startup Shows UCSD Technology Can Boost Immune Response to Cancer in Mice
|
Bruce V. Bigelow |
10/14/09 |
San Diego
|
|
Celladon, Developer of Gene Therapy for Heart Failure, Secures Part of $24.6M Venture Round
|
Luke Timmerman |
09/15/09 |
San Diego
|
|
Arena Prepares to Release Big Obesity Study, Minnow Medical Goes Into ‘Commercialization Mode,’ Metabasis Hires Strategic Adviser, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
09/10/09 |
San Diego
|
|
Targeted Genetics Lives On, CellCyte Charged With Fraud, Theraclone Finds HIV Weakness, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
09/10/09 |
Seattle
|
|
Targeted Genetics Survives Brush With Death, Sells Gene Therapy IP to Genzyme for $7M
|
Luke Timmerman |
09/09/09 |
National
|
|
AVI Offers Glimmer of Hope for Muscular Dystrophy, Says UW Neuroscientist Jeff Chamberlain
|
Luke Timmerman |
09/01/09 |
Seattle
|
|
Targeted Genetics’ Legacy: No Cures, But a Generation of Seattle Biotechies
|
Luke Timmerman |
08/25/09 |
Seattle
|
|
Why Big Pharma Wants To Be Like Big Biotech
|
Stewart Lyman |
08/19/09 |
National
|
|
Targeted ‘Must Raise’ Cash
|
Luke Timmerman |
08/12/09 |
Seattle
|
|
Targeted Genetics Amends Lease
|
Luke Timmerman |
07/24/09 |
Seattle
|
|
Targeted Genetics Dumps Lease, Amgen’s Dmab Works in Cancer Trial, Theraclone Nabs Cash, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
07/09/09 |
Seattle
|
|
Targeted Genetics Sheds Lease
|
Luke Timmerman |
07/06/09 |
Seattle
|
|
Targeted Genetics Cuts Workforce in Half in Bid to Survive Into August
|
Luke Timmerman |
06/22/09 |
Seattle
|
|
Amylin Dissidents Win Board Seats, Targeted Genetics’ Troubles Raise Gene Therapy Concerns, Celladon Eyes Partnership, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
06/04/09 |
San Diego
|
|
Experimental Gene Therapy for Blindness Will Proceed Even if Targeted Genetics Goes Dark
|
Denise Gellene |
06/03/09 |
San Diego
|
|
Celladon CEO Upbeat on Gene Therapy for Heart
|
Denise Gellene |
05/29/09 |
San Diego
|
|
David M. Bodine Q&A: Making Progress on Gene Therapy, Despite Targeted Genetics’ Woes
|
Denise Gellene |
05/27/09 |
San Diego
|
|
Targeted Genetics, Mainstay of Gene Therapy, Faces Likely Shutdown
|
Luke Timmerman |
05/07/09 |
Seattle
|
|
Genzyme Enters Seattle Hub, Oncothyreon Bets on Cancer Drugs, Pathway Nabs $40M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
04/02/09 |
Seattle
|
|
Targeted Ends Year With $5.2M
|
Luke Timmerman |
03/31/09 |
Seattle
|
|
Genzyme Gene Therapy Fails To Help People with Leg Disease Walk Longer
|
Luke Timmerman |
03/31/09 |
Boston
|
|
Sticking to its Guns with Gene Therapy, Genzyme To Present Key Findings Within Days
|
Luke Timmerman |
03/25/09 |
Boston
|
|
Biogen Idec Aims to Regenerate Damaged Nerves, Crack Multi-Billion Dollar Market
|
Luke Timmerman |
03/11/09 |
Boston
|
|
Targeted Genetics Hands Off Manufacturing
|
Luke Timmerman |
03/02/09 |
Seattle
|
|
Biogen Idec Takes Aim at New Parkinson’s Paradigm
|
Luke Timmerman |
01/05/09 |
Boston
|
|
Ceregene Drug Fails in Parkinson’s Trial
|
Luke Timmerman |
12/01/08 |
San Diego
|
|
Stewart Parker Resigns from Board of Targeted Genetics, Susan Robinson Takes Her Spot
|
Luke Timmerman |
11/17/08 |
Seattle
|
|
Stewart Parker Resigns from Targeted Genetics After Gene Therapy Setbacks
|
Luke Timmerman |
11/10/08 |
Seattle
|
|
Targeted Genetics Cash Will Stretch into First Quarter
|
Luke Timmerman |
11/05/08 |
Seattle
|
|
Ceregene Awaits Parkinson’s Trial Results, In a Key Test for Gene Therapy
|
Luke Timmerman |
10/31/08 |
San Diego
|
|
Page 1 of
2 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
